The startup develops neuronal therapeutics that enhance neuroplasticity and strengthen neuronal connections to treat central neurologic and psychiatric disorders. Their therapies aim to restore healthy brain function by rebalancing signaling mechanisms, providing patients and healthcare providers with effective treatment options for central nervous system conditions.
Funding
$45.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Synaptic dysfunction, characterized by weakened or lost connections between neurons, underlies many central nervous system (CNS) disorders, including depression, Alzheimer's disease, and schizophrenia, impacting over one billion people globally. Current treatments often fail to address the underlying synaptic biology of these conditions.
Solution
Syndeio Biosciences is developing a new class of precision neurotherapeutics that target synaptic health to treat neuropsychiatric and cognitive disorders. The company's approach leverages event-driven pharmacology, where a single dose of a drug candidate triggers lasting biological changes that strengthen neuronal connections. Syndeio's pipeline includes both injectable and oral NMDAR (N-methyl-D-aspartate receptor) positive allosteric modulators (PAMs) designed to enhance glutamate signaling and improve synaptic function. These therapies aim to restore healthy brain function by activating the brain’s ability to form new neural connections, offering a potentially safer and more effective alternative to existing treatments. Syndeio utilizes precision neuroscience, incorporating biomarkers, quantitative EEG, brain wave analyses, machine learning, and polysomnography to optimize patient outcomes.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric and cognitive disorders such as depression, Alzheimer's disease, and schizophrenia, as well as healthcare providers seeking novel and effective treatment options for these conditions.
Features
- Zelquistinel: An oral NMDAR PAM in Phase 2 clinical trials for major depressive disorder (MDD) and planned trials for Alzheimer's disease, designed to enhance glutamate signaling and improve synaptic function.
- Apimostinel: An injectable NMDAR PAM for rapid-acting treatment of severe CNS disorders, currently in a Phase 2a trial in collaboration with the University of Pittsburgh, paired with a digital therapy to enhance neuroplasticity-driven benefits.
- Boost™: A proprietary synapse pharmacology platform integrating molecular, functional, and behavioral models to explore how molecules impact neuronal networks and synaptogenesis.
- Targeted medicine approach using objective biomarkers, quantitative EEG, brain wave analyses, machine learning, and polysomnography.
- Clinical partnership with Beacon Biosignals, employing their FDA 510(k)-cleared DREEM 3S device to capture biomarkers in clinical studies.